

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	41,634	84.3%	2,759	94.4%	14,414	97.3%	1,212	21.9%	2,411	95.4%
Squamous cell carcinoma (8070-8078,8083-8084)	40,643	82.3%	2,645	90.5%	14,168	95.6%	1,160	20.9%	2,385	94.4%
Adenocarcinoma ^c	5,033	10.2%	116	4.0%	223	1.5%	3,392	61.2%	83	3.3%
Other specific carcinomas ^d	514	1.0%	-	-	37	0.2%	306	5.5%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,611	3.3%	-	-	79	0.5%	414	7.5%	-	-
Sarcoma and soft tissue ^e	153	0.3%	-	-	19	0.1%	33	0.6%	-	-
Other specific types ^f	264	0.5%	17	0.6%	16	0.1%	115	2.1%	-	-
Unspecified (8000-8005)	183	0.4%	-	-	33	0.2%	70	1.3%	-	-
Total	49,393	100.0%	2,923	100.0%	14,821	100.0%	5,542	100.0%	2,526	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	5,360	80.9%	1,717	62.4%	10,307	97.5%	2,712	96.9%	742	89.1%
Squamous cell carcinoma (8070-8078,8083-8084)	5,111	77.1%	1,566	56.9%	10,185	96.4%	2,691	96.1%	732	87.9%
Adenocarcinoma ^c	1,034	15.6%	87	3.2%	64	0.6%	16	0.6%	18	2.2%
Other specific carcinomas ^d	42	0.6%	39	1.4%	41	0.4%	21	0.8%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	57	0.9%	843	30.6%	121	1.1%	35	1.3%	35	4.2%
Sarcoma and soft tissue ^e	31	0.5%	34	1.2%	-	-	-	-	-	-
Other specific types ^f	86	1.3%	16	0.6%	-	-	-	-	-	-
Unspecified (8000-8005)	17	0.3%	17	0.6%	20	0.2%	-	-	-	-
Total	6,628	100.0%	2,753	100.0%	10,568	100.0%	2,799	100.0%	833	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.